PRESS RELEASE

IgGenix Announces Presentations on Future of Food Allergy Treatment at Gordon Research Conference

SOUTH SAN FRANCISCO, Calif. – November 10, 2022 – IgGenix, Inc., a pre-clinical biotechnology company taking a revolutionary approach to directly address allergic disease, today announced that three presentations will be given by IgGenix co-founders at the upcoming the Food Allergy Gordon Research Conference to be held November 13-18, 2022, in Oxnard, California.

“IgGenix is deeply invested in transforming the approach to allergy treatment by pioneering a molecular understanding of allergic disease,” said IgGenix co-founder and Chief Technology Officer Derek Croote, Ph.D. “We are eager to gather with other leaders in the food allergy community to share how the translation of our research has the potential to revolutionize the standard of allergy care for the millions who suffer from allergic disease, including myself.”

Food allergies impact approximately 32 million Americans and 200 million people globally, and their incidence is on the rise. Every three minutes, someone visits an emergency room for food-induced anaphylaxis. IgGenix is driven to develop safer therapeutics with a faster onset of action and a more sustained clinical response through the re-engineering of human monoclonal IgE antibodies.

Presentation Details

Climate Change and Health: Problem and Solution Based Research Approaches

  • Speaker: Kari Nadeau, M.D., Ph.D., F.A.A.A.A.I.
  • Date and Time: Sunday, November 13, 7:50 pm – 8:30 pm PT

Single Cell Genomics and Allergies

  • Speaker: Stephen Quake, D. Phil.
  • Date and Time: Tuesday, November 15, 11:30 am – 11:55 am PT

Unbiased Human IgE Antibody Discovery Yields High-Affinity Antibodies Against Numerous Diverse Allergens

  • Speaker: Derek Croote, Ph.D.
  • Date and Time: Tuesday, November 15, 8:30 pm – 8:55 pm PT

About IgGenix

IgGenix is a privately held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by reengineering key antibodies involved in the allergic cascade. Founded based on research by professors Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, IgGenix isolates allergen-specific IgE antibodies using its SEQ SIFTER™ discovery platform. IgGenix then re-engineers these IgE antibodies into IgG antibodies designed to inhibit the allergic cascade. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects people living with severe allergies.   

Contact

For Investor Inquiries:  
Jessica Grossman 
jgrossman@iggenix.com  

For Media Inquiries:  
Janine Bogris  
202-470-5213 
jbogris@jpa.com